Lightbits Labs Launches Industry’s First NVMe/TCP Clustered Storage Solution
11.12.2019 16:00:00 EET | Business Wire | Press release
Lightbits Labs, the leader in NVMe™ over TCP (NVMe/TCP) software-defined disaggregated storage, today has advanced its software solution, LightOS, to deliver the first NVMe/TCP clustered storage solution.
With more companies moving away from direct attached storage (DAS), and with storage requirements typically growing far faster than compute requirements, both public-cloud providers and private-cloud builders are looking for ways to separate storage and compute so each can scale separately. One of the limiting factors to scaling disaggregated storage, however, is the need for high availability across clusters of storage and compute. Lightbits LightOS delivers the availability, flexibility and efficiency of hyperscale cloud infrastructure to on-premise data centers.
LightOS is now the first NVMe/TCP storage solution that protects against data loss and avoids service interruptions at scale. In the presence of server, storage, or network failures, LightOS maximizes operational efficiency, ensuring applications continue working in the presence of failures, and failover is handled automatically, keeping data fully consistent and available.
The average cost of IT downtime is enormous. According to Gartner, the average loss is $5,600 per minute. This can add up to more than half a million dollars lost per hour at the higher end.
“At cloud scale, everything fails, so we built LightOS to capture all the benefits of disaggregated storage while providing exceptional durability and availability to prevent service disruption,” said Kam Eshghi, Chief Strategy Officer at Lightbits Labs.
For cloud-native applications, access to available, performant and easily deployable infrastructure is key to business agility and application experience, at any scale - regardless of whether you deploy five nodes, five hundred nodes, or thousands of nodes.
Installed on commodity servers in large-scale data centers, LightOS is optimized for I/O intensive compute clusters, such as Cassandra, MySQL, MongoDB, and time series databases. With end-to-end NVMe, LightOS delivers high performance and consistently low latency. The result is a 10X increase in storage reliability and 50% decrease in total cost of ownership (TCO). As a standard-based, target-only solution that does not require installing any proprietary software on the client side, the ease of deployment at scale is unmatched. LightOS is built to run in your existing data center, requiring no changes to application servers or your network infrastructure, so that deploying it at scale is a breeze.
As LightOS provides highly available, flexible, and efficient disaggregated storage, application teams can focus their efforts on developing new services to achieve their business goals, while lowering spend and delivering high performance.
LightOS provides the following additional benefits:
- Software-defined disaggregated storage for cloud data centers delivering similar performance as direct-attached NVMe SSDs and up to a 50% reduction in tail latency.
- Independent scaling of storage and compute, driving better infrastructure utilization and efficiency and providing unparalleled flexibility.
- Standards-based NVMe/TCP block storage access protocol for application servers to storage servers communication.
- LightOS clusters leverage standard NVMe 1.4 multipathing and offers data replications on storage target side, which provides transparency to the client with quick failover.
- Distributed and durable cluster management with fast failover handling.
- No single point of failure in data and control paths.
- Multiple LightOS clusters can exist in the same cloud data center and can be easily aggregated and managed as one large cloud-scale block storage solution.
Lightbits Labs Resources
- Deploying Reliable High Performance Storage with LightOS
- Meet Lightbits: Separation without Drama
- Lightbits Labs Named Storage Company of the Year (press release)
- LightOS and LightField announcement (press release)
For additional information, contact info@lightbitlabs.com
About Lightbits Labs™
Lightbits Labs, founded in 2016, is remaking modern cloud infrastructure on a global scale. The company’s mission is to reinvent the way storage and networking are conducted in data centers. As trailblazers in this field, its solutions are successfully being used in industry-leading private cloud and enterprise data centers around the globe. With strategic investors including Dell Technology Capital and Micron, and with investments from Chairman and co-founder Avigdor Willenz (Founder of Annapurna and Galileo), Lip-Bu Tan (CEO of Cadence and chairman of Walden International) and Marius Nacht (Co-Founder and Chairman of Check Point Software), Lightbits Labs is disaggregating storage and compute to improve performance and TCO. Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005163/en/
Contact information
Marianne Dempsey
On behalf of Lightbits Labs
mdempsey@rainierco.com
508-475-0025 ext. 115
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
